Target intelligence / Profile preview

Cyclin-dependent kinase 7 (CDK7) (CDK7)

Target
CDK7
Molecular classification
Enzyme, Kinase, Transcription factor complex, Serine/threonine protein kinase, Cyclin-dependent kinase
01

Overview

This target refers to the host cell enzymatic machinery responsible for the phosphorylation of the Serine 5 (Ser5) residue within the C-terminal domain (CTD) of RNA polymerase II (Pol II). The central component of this machinery is Cyclin-dependent kinase 7 (CDK7), which functions as the catalytic subunit of the general transcription factor II H (TFIIH) complex. Serine 5 phosphorylation is a prerequisite for the transition of Pol II from the initiation phase to the elongation phase and is critical for the recruitment of mRNA capping enzymes. Many DNA viruses, including Herpes Simplex Virus Type 1 (HSV-1), hijack these host factors to facilitate their own gene expression and replication. Recent research has highlighted that specific phloroglucinol derivatives, such as those isolated from Rhodomyrtus tomentosa, can inhibit viral replication by blocking these host factors, thereby preventing the expression of the transcriptionally active Ser5-phosphorylated form of RNA polymerase. Targeting this host-dependency represents a novel antiviral strategy that may overcome resistance to standard nucleoside analogues, although it carries risks of systemic toxicity due to the inhibition of essential cellular transcription and cell cycle progression.

Other names
Host cell factors involved in serine 5-phosphorylated RNA polymerase expressionRNA polymerase II C-terminal domain Serine 5 kinaseCDK-activating kinase (CAK)TFIIH subunit CDK7Cyclin-dependent kinase 7
02

Mechanism of action

Inhibition of the CDK7 kinase activity within the TFIIH complex, which prevents the phosphorylation of the Serine 5 residue on the C-terminal domain of RNA polymerase II, thereby blocking the transition from transcription initiation to elongation and arresting the expression of viral and host genes.

03

Biological functions

Transcription initiationCell cycle regulationPromoter escapemRNA capping recruitmentTranscription-coupled DNA repair
04

Disease associations

InfectionCancerHerpes simplex virus 1 (HSV-1) infectionRespiratory syncytial virus (RSV) infectionInflammation
05

Safety considerations

Broad-spectrum inhibition of host transcriptionGastrointestinal toxicityNeutropeniaPotential for systemic toxicity due to cell cycle interferenceAnemia
06

Interacting drugs

Compound 6 (Rhodomyrtus phloroglucinol derivative)

5 more in the full profile.

07

Biomarkers

Serine 5-phosphorylated RNA polymerase II levelsCDK7 expression levelsCyclin H levelsc-Myc expression

Beyond the preview

Go deeper on Cyclin-dependent kinase 7 (CDK7) (CDK7).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cyclin-dependent kinase 7 (CDK7) (CDK7).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call